Forbes August 7, 2024
Rita Numerof

On the heels of the FTC’s investigation into pharmacy benefit managers for what many regard as anti-competitive business practices, legal pressure is continuing to mount. At least six state Attorneys General, including California, Ohio and most recently Vermont, have initiated lawsuits against PBMs. Additionally, recent House oversight investigation findings bolster these claims, revealing that these drug middlemen–who claim to control costs–have instead “steered patients toward higher-priced medicines and affiliated pharmacies.”

As these inquiries, investigations and lawsuits keep PBM practices in the public eye, it’s important that lawmakers, employers and the general public understand not just what these practices are but how they relate to the larger healthcare market. PBMs are one piece of the jigsaw puzzle of healthcare, and they...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Congress / White House, Employer, Govt Agencies, Pharma, Pharma / Biotech
Pharma Pulse 11/25/24: Deepening Patient Relationships, Menopause May Increase Risk of Asthma & more
Trump tariffs could drive up generic drug costs: 5 takeaways
Bridging the Gap: Pharmacists' Role in Advancing Pharmacogenomic Testing Standards
The Evolving Role of Pharmacists in Custom Pathway Implementation
Pharma Pulse 11/25/24: Deepening Patient Relationships,

Share This Article